<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37165399</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>76</StartPage><MedlinePgn>76</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">76</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03057-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Systemic lupus erythematosus (SLE) is an intractable disease characterized by autoantibody production and autoreactive B and T cell proliferation. Although several studies have revealed multiple genetic and environmental associations, the underlying mechanisms remain unknown.</AbstractText><AbstractText Label="METHODS">We performed proteomics and transcriptomics using liquid chromatography-mass spectrometry and DNA microarray, using peripheral blood B cells from patients with SLE, and healthy controls (HC). We explored molecules associated with the pathophysiology of SLE by flow cytometry and B cell stimulation assay.</AbstractText><AbstractText Label="RESULTS">We identified for the first time that expression of both S100A8 protein and mRNA were markedly upregulated in SLE B cells. The results obtained using flow cytometry showed that S100A8 was highly expressed on the surface of B cells of patients with active SLE (MFI; HC 102.5&#x2009;&#xb1;&#x2009;5.97, stable SLE 111.4&#x2009;&#xb1;&#x2009;12.87, active SLE 586.9&#x2009;&#xb1;&#x2009;142.9), and S100A8 on the cell surface was decreased after treatment (MFI; pre-treat 1094.5&#x2009;&#xb1;&#x2009;355.38, post-treat 492.25&#x2009;&#xb1;&#x2009;247.39); therefore, it is suggested that S100A8 may be a marker for disease activity. The mRNA expression of S100A8 was particularly upregulated in memory B cells of SLE (56.68 fold higher than HC), suggesting that S100A8 may be mainly secreted by memory B cells in the pathogenesis of SLE.</AbstractText><AbstractText Label="CONCLUSIONS">Our results imply that the S100A8 proteins secreted from memory B cells may stimulate granulocytes and monocytes through pattern recognition receptors, activate the innate immune system, and are involved in the pathogenesis of SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitagori</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oku</LastName><ForeName>Takuma</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Portfolio &amp; Science, Astellas Pharma Inc, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Omics Research Center, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Kosaku</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirayama</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Portfolio &amp; Science, Astellas Pharma Inc, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishihama</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmura</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kobe City Medical Center General Hospital, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morinobu</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimori</LastName><ForeName>Tsuneyo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ijinkai Takeda General Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshifuji</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. yossii@kuhp.kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D040501">Calgranulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040501" MajorTopicYN="Y">Calgranulin A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cells</Keyword><Keyword MajorTopicYN="N">S100A8</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37165399</ArticleId><ArticleId IdType="pmc">PMC10170829</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03057-z</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03057-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23:615&#x2013;635. doi: 10.1016/j.molmed.2017.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.05.006</ArticleId><ArticleId IdType="pmc">PMC5650102</ArticleId><ArticleId IdType="pubmed">28623084</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1&#x2013;13. doi: 10.1016/j.jaut.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term Belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62:201&#x2013;210. doi: 10.1002/art.27189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27189</ArticleId><ArticleId IdType="pmc">PMC2857977</ArticleId><ArticleId IdType="pubmed">20039404</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of Belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731. doi: 10.1016/S0140-6736(10)61354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of Belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168&#x2013;1178. doi: 10.1002/art.24699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24699</ArticleId><ArticleId IdType="pmc">PMC2758229</ArticleId><ArticleId IdType="pubmed">19714604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1265&#x2013;1272. doi: 10.1074/mcp.M500061-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M500061-MCP200</ArticleId><ArticleId IdType="pubmed">15958392</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology. 2017;56:1662&#x2013;2017. doi: 10.1093/rheumatology/kew431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew431</ArticleId><ArticleId IdType="pubmed">28122959</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49:725&#x2013;739. doi: 10.1016/j.immuni.2018.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192:5459&#x2013;5468. doi: 10.4049/jimmunol.1002795.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002795</ArticleId><ArticleId IdType="pmc">PMC4083591</ArticleId><ArticleId IdType="pubmed">24907379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugtveit J, Scott H, Halstensen TS, Fausa O, Brandtzaeg P. Differential expression of leucocyte protein L1 (calprotectin) by monocytes and intestinal macrophages. Adv Exp Med Biol. 1995;371A:207&#x2013;210. doi: 10.1007/978-1-4615-1941-6_42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1941-6_42</ArticleId><ArticleId IdType="pubmed">8525907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagasse E, Clerc RG. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation. Mol Cell Biol. 1988;8:2402&#x2013;2410. doi: 10.1128/mcb.8.6.2402-2410.1988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.8.6.2402-2410.1988</ArticleId><ArticleId IdType="pmc">PMC363438</ArticleId><ArticleId IdType="pubmed">3405210</ArticleId></ArticleIdList></Reference><Reference><Citation>Murao S, Collart F, Huberman E. A protein complex expressed during terminal differentiation of monomyelocytic cells is an inhibitor of cell growth. Cell Growth Differ. 1990;1:447&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">2278876</ArticleId></ArticleIdList></Reference><Reference><Citation>Yui S, Mikami M, Yamazaki M. Purification and characterization of the cytotoxic factor in rat peritoneal exudate cells: its identification as the calcium binding protein complex, calprotectin. J Leukoc Biol. 1995;58:307&#x2013;316. doi: 10.1002/jlb.58.3.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.58.3.307</ArticleId><ArticleId IdType="pubmed">7665986</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandtzaeg P, Gabrielsen TO, Dale I, M&#xfc;ller F, Steinbakk M, Fagerhol MK. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol. 1995;371A:201&#x2013;206. doi: 10.1007/978-1-4615-1941-6_41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1941-6_41</ArticleId><ArticleId IdType="pubmed">8525906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrchen JM, Sunderk&#xf6;tter C, Foell D, Vogl T, Roth J. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557&#x2013;566. doi: 10.1189/jlb.1008647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1008647</ArticleId><ArticleId IdType="pubmed">19451397</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042&#x2013;1049. doi: 10.1038/nm1638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1638</ArticleId><ArticleId IdType="pubmed">17767165</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008;102:1239&#x2013;1246. doi: 10.1161/CIRCRESAHA.107.167544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.107.167544</ArticleId><ArticleId IdType="pubmed">18403730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14) J Infect Dis. 2000;182:1272&#x2013;1275. doi: 10.1086/315810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315810</ArticleId><ArticleId IdType="pubmed">10979933</ArticleId></ArticleIdList></Reference><Reference><Citation>Odink K, Cerletti N, Br&#xfc;ggen J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987;330:80&#x2013;82. doi: 10.1038/330080a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/330080a0</ArticleId><ArticleId IdType="pubmed">3313057</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499&#x2013;505. doi: 10.1136/annrheumdis-2013-203923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203923</ArticleId><ArticleId IdType="pubmed">24297376</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotectin&#x2014;a promising diagnostic marker for adult-onset Still&#x2019;s disease. Clin Rheumatol. 2016;35:73&#x2013;79. doi: 10.1007/s10067-015-3108-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3108-6</ArticleId><ArticleId IdType="pmc">PMC4710651</ArticleId><ArticleId IdType="pubmed">26547221</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjogren&#x2019;s syndrome. Scand J Rheumatol. 2014;43:76&#x2013;78. doi: 10.3109/03009742.2013.848930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2013.848930</ArticleId><ArticleId IdType="pubmed">24295066</ArticleId></ArticleIdList></Reference><Reference><Citation>Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62:880&#x2013;884. doi: 10.1097/JIM.0000000000000095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JIM.0000000000000095</ArticleId><ArticleId IdType="pubmed">24922195</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;gering N, Stoll R, Kucharzik T, Schmid KW, Rohlmann G, Burmeister G, et al. Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn&#x2019;s disease. Digestion. 1995;56:406&#x2013;414. doi: 10.1159/000201267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000201267</ArticleId><ArticleId IdType="pubmed">8549885</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;gering N, Stoll R, Schmid KW, Kucharzik T, Stein H, Burmeister G, et al. The myeloic related protein MRP8/14 (27E10 antigen)&#x2014;usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Eur J Clin Investig. 1995;25:659&#x2013;664. doi: 10.1111/j.1365-2362.1995.tb01982.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.1995.tb01982.x</ArticleId><ArticleId IdType="pubmed">7498239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyd&#xe9;n H, Lood C, Gullstrand B, J&#xf6;nsen A, Ivars F, Leanderson T, et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. Lupus. 2017;26:139&#x2013;149. doi: 10.1177/0961203316655208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316655208</ArticleId><ArticleId IdType="pubmed">27407135</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CH, Adav SS, Sze SK, Choong YK, Saravanan R, Schmidtchen A. Thrombin and plasmin alter the proteome of neutrophil extracellular traps. Front Immunol. 2018;9:1554. doi: 10.3389/fimmu.2018.01554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01554</ArticleId><ArticleId IdType="pmc">PMC6046383</ArticleId><ArticleId IdType="pubmed">30038618</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015;27:448&#x2013;453. doi: 10.1097/BOR.0000000000000197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000197</ArticleId><ArticleId IdType="pubmed">26125102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki S, Konno Y, Takeda M, Moritoki Y, Hirokawa M, Matsuwaki Y, et al. Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes. J Allergy Clin Immunol. 2016;137:258&#x2013;267. doi: 10.1016/j.jaci.2015.04.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.04.041</ArticleId><ArticleId IdType="pmc">PMC4674385</ArticleId><ArticleId IdType="pubmed">26070883</ArticleId></ArticleIdList></Reference><Reference><Citation>Loures FV, R&#xf6;hm M, Lee CK, Santos E, Wang JP, Specht CA, et al. Recognition of Aspergillus fumigatus hyphae by human plasmacytoid dendritic cells is mediated by dectin-2 and results in formation of extracellular traps. PLOS Pathog. 2015;11:e1004643. doi: 10.1371/journal.ppat.1004643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004643</ArticleId><ArticleId IdType="pmc">PMC4450068</ArticleId><ArticleId IdType="pubmed">25659141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha Arrieta YC, Rojas M, Vasquez G, Lopez J. The lymphocytes stimulation induced DNA release, a phenomenon similar to NETosis. Scand J Immunol. 2017;86:229&#x2013;238. doi: 10.1111/sji.12592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12592</ArticleId><ArticleId IdType="pubmed">28805301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>